Cystic Fibrosis Clinical Trial
Official title:
Reducing the Effects of Air Pollution on Children With Cystic Fibrosis
1. To determine personal exposure to air pollution in children with cystic fibrosis;
2. To determine airway macrophage uptake of inhaled particulate matter in cystic fibrosis
children;
3. To establish whether prostaglandin E2 affects particulate matter removal in airway.
Background:
Cystic fibrosis (CF) is the commonest hereditary life-shortening respiratory condition,
resulting in premature death secondary to recurrent airway infections and inflammation,
leading to irreversible lung damage. The screening programme in infancy has improved life
expectancy but the lifespan of CF patients is still reduced by 20 years at present. Thus
interventions to reduce inflammation, infection and lung damage in CF are still needed.
One potential intervention is to reduce exposure of CF children to air pollution. Particulate
matter (PM) are microscopic soot particles from petrol and diesel engine emissions; PM is
linked to adverse respiratory health effects in children. Children with cystic fibrosis are
particularly vulnerable to PM but, to date, no exposure-reduction advice is available, and
the mechanism underlying this vulnerability is unclear.
Personal exposure of CF children to PM is due to: i) locally-generated sources (relative to
the proximity to busy roads) and ii) background concentrations (i.e. PM blown across the
whole city from other areas). Although a link between air pollution and reduced lung function
growth in healthy children is well established, the link with CF lung disease has only
recently emerged. A recent study found that long-term exposure of CF children to PM increases
risk of airway infection with Pseudomonas. Another study also found that short-term
background pollution is associated with increased need for antibiotics in children and adults
with CF. The need to reduce patients' personal exposure to PM has been recognised by Barts
Health NHS Trust. Working with Global Action Plan, the Trust has developed tips on how to
reduce adults' personal exposure to air pollution. These tips include traveling outside rush
hours, taking low pollution routes (maps provided), and signing up to the airText air
pollution warning App. Since travel outside rush hours is not feasible for school children,
child-friendly tips are urgently needed.
Recent research in asthma patients suggests a putative mechanism of impaired removal of
inhaled PM. In the healthy lung, inhaled PM is quickly removed (phagocytosed) by airway
macrophages (AM). AM patrol the surface of epithelial cells lining the airways; after taking
up PM, they move up and out of the lung. Thus AM with normal phagocytic function act to both
reduce PM exposure of other airway cells - including epithelial cells, and to ensure that PM
does not accumulate in the lung. The amount of carbon particles in AM was previously used to
assess the effects of long-term effects of exposure of healthy children and adults. The
amount of black carbon (BC) in AM reflects the intrinsic capacity of AM to remove PM
(phagocytic capacity). AM carbon is significantly lower in conditions such as severe asthma,
where AM phagocytic capacity is impaired. Furthermore, a role for prostaglandin E2 (PGE2) in
mediating impaired phagocytic function in asthma has been identified. First, PGE2 suppresses
AM phagocytosis of urban PM in vitro; and second, children with severe asthma had increased
urinary PGE2 metabolites. Shift of inhaled PM away from AM to other cells has the potential
to stimulate interleukin-8 (IL-8) release by epithelial cells - a phenomenon observed in
mouse, where inhalation of non-inflammatory particles produces significant airway
neutrophilia when AM phagocytic function is impaired.
The hypothesis is that impaired handling of inhaled PM by AM contributes to vulnerability of
children with CF to air pollution. Specifically, increased vulnerability to inhaled PM in
children with CF is due to PGE2-mediated impairment of AM phagocytosis. The corollary is that
children with CF will have; i) reduced levels of AM carbon in vivo (reflecting reduced
phagocytosis of inhaled PM in vivo), ii) reduced capacity of AM to phagocytose carbon PM in
vitro, iii) increased metabolites of PGE2 in the airway and urine, and finally, iv) since
PGE2 production is under the control of the enzyme cyclooxygenase (COX, especially COX-2), CF
airway cells have increased COX-2 expression, v) COX inhibitors (e.g. Ibuprofen) should
suppress PGE2 production, theoretically improving AM function.
Non-cystic fibrosis bronchiectasis is a respiratory condition with multiple aetiology such as
congenital pathology, immunodeficiency, and primary ciliary dyskinesia. Patients with non-CF
bronchiectasis demonstrate similar clinical features to those with CF, patients with either
conditions are managed with similar treatments, it is therefore hypothesised that the above
also apply to children with non-CF bronchiectasis.
There has been evidence that some organisms are capable of reproducing and residing within
airway macrophages without being destroyed by the traditional phagocytic pathway. Often,
unwell CF and non-CF bronchiectasis patients are admitted to the hospital for intensive
antibiotic treatments but a proportion of their sputum samples yield no growth by routine
hospital culture. This study will explore isolated airway macrophages and identify the
organisms within - if any are present.
Clinical Data:
There is evidence to support this hypothesis; i) it was previously reported that phagocytosis
of inert latex beads is impaired in AM from CF adults (71 + 15 % phagocytosis in controls vs.
23 + 9 % in CF), ii), CF is associated with increased airway PGE2, and iii) in a pilot study,
significantly (p<0.01) reduced AM carbon in 6 CF children compared with 6 healthy controls
(mean 0 vs. 0.3 + .05, μm2 p<0.01) was found.
Rationale:
To date, the effect of impaired uptake of PM by AM on other airway cells has not been studied
in vitro. The hypothesis is that in co-cultures of human AM and airway epithelial cells
exposed to urban PM, PGE2-mediated impairment of macrophage phagocytosis increases epithelial
release of IL-8. Furthermore, since AM are a major source of airway PGE2, it is speculated
that there is increased COX-2 expression in AM from CF children. Thus suppression of AM
phagocytic function in CF is an autocrine process; i.e. CF AM release more PGE2 - which in
turn suppresses AM phagocytosis. In this study the evidence will be sought for abnormal
handling of PM by AM from CF children, and model this using cultures of human airway cells
and macrophages.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |